STAT3 and neoplasm: Response to anti-PD-L1 therapy has been correlated with PD-L1 expression in tumor and immune cells, alterations in PIK3/AKT pathway, STAT3/JAK3 pathway, specific neoantigens expression, and mutational load27, 43, 44, 45, 46, 47.